|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastric emptying evaluation by ultrasound prior colonoscopy:An easy tool following bowel preparation显示文摘AIM: To investigate the gastric emptying after bowel preparation to allow general anaesthesia. METHODS: A prospective, non-comparative, and nonrandomized trial was performed and registered on Eudra CT database(2011-002953-80) and on www.trial.gov(NCT01398098). All patients had a validated indication for colonoscopy and a preparation using sodium phosphate(NaP) tablets. The day of the procedure, patients took 4 tablets with 250 mL of water every 15 min, three times. The gastric volume wasestimated every 15 min from computed antral surfaces and weight according to the formula of Perlas et al(Anesthesiology, 2009). Colonoscopy was performed within the 6 h following the last intake.RESULTS: Thirty patients were prospectively included in the study from November 2011 to May 2012. The maximum volume of the antrum was 212 mL, achieved 15 min after the last intake. 24%, 67% and 92% of subjects had an antral volume below 20 mL at 60, 120 and 150 min, respectively. 81% of patients had a Boston score equal to 2 or 3 in each colonic segment. No adverse events leading to treatment discontinuation were reported.CONCLUSION: Gastric volume evaluation appeared to be a simple and reliable method for the assessment of gastric emptying. Data allow considering the NaP tablets bowel preparation in the morning of the procedure and confirming that gastric emptying is achieved after two hours, allowing general anaesthesia. | Romain Coriat Vanessa Polin Ammar Oudjit Franck Henri Marion Dhooge Sarah Leblanc Chantal Delchambre Anouk Esch Tessa Tabouret Maximilien Barret Frédéric Prat Stanislas Chaussade | 2014 | World Journal of Gastroenterology2014，20，37： | 6 |
| 2 | Cytomegalovirus in inflammatory bowel disease: Asystematic review显示文摘AIM: To identify definitions of cytomegalovirus(CMV) infection and intestinal disease, in inflammatory bowel disease(IBD), to determine the prevalence associated with these definitions.METHODS: We conducted a systematic review and interrogated Pub Med, EMBASE and Cochrane for literature on prevalence and diagnostics of CMV infection and intestinal disease in IBD patients. As medical headings we used 'cytomegalovirus' OR 'CMV' OR 'cytomegalo virus' AND 'inflammatory bowel disease' OR 'IBD' OR 'ulcerative colitis' OR 'colitis ulcerosa' OR 'Crohn's disease'. Both Me SH-terms and free searches were performed. We included all types of English-language(clinical) trials concerning diagnostics and prevalence of CMV in IBD.RESULTS: The search strategy identified 924 citations, and 52 articles were eligible for inclusion. We identified 21 different definitions for CMV infection, 8 definitions for CMV intestinal disease and 3 definitions for CMV reactivation. Prevalence numbers depend on used definition, studied population and region. The highest prevalence for CMV infection was found when using positive serum PCR as a definition, whereas for CMV intestinal disease this applies to the use of tissue PCR > 10 copies/mg tissue. Most patients with CMV infection and intestinal disease had steroid refractory disease and came from East Asia.CONCLUSION: We detected multiple different definitions used for CMV infection and intestinal disease in IBD patients, which has an effect on prevalence numbers and eventually on outcome in different trials. | Tessa EH Römkens Geert J Bulte Loes HC Nissen Joost PH Drenth | 2016 | World Journal of Gastroenterology2016，22，3： | 6 |
| 3 | Malaria: Global progress 2000-2015 and future challenges显示文摘Background:2015 was the target year for malaria goals set by the World Health Assembly and other international institutions to reduce malaria incidence and mortality.A review of progress indicates that malaria programme financing and coverage have been transformed since the beginning of the millennium,and have contributed to substantial reductions in the burden of disease.Findings:Investments in malaria programmes increased by more than 2.5 times between 2005 and 2014 from US$960 million to US$2.5 billion,allowing an expansion in malaria prevention,diagnostic testing and treatment programmes.In 2015 more than half of the population of sub-Saharan Africa slept under insecticide-treated mosquito nets,compared to just 2%in 2000.Increased availability of rapid diagnostic tests and antimalarial medicines has allowed many more people to access timely and appropriate treatment.Malaria incidence rates have decreased by 37%globally and mortality rates by 60%since 2000.It is estimated that 70%of the reductions in numbers of cases in sub-Saharan Africa can be attributed to malaria interventions.Conclusions:Reductions in malaria incidence and mortality rates have been made in every WHO region and almost every country.However,decreases in malaria case incidence and mortality rates were slowest in countries that had the largest numbers of malaria cases and deaths in 2000;reductions in incidence need to be greatly accelerated in these countries to achieve future malaria targets.Progress is made challenging because malaria is concentrated in countries and areas with the least resourced health systems and the least ability to pay for system improvements.Malaria interventions are nevertheless highly cost-effective and have not only led to significant reductions in the incidence of the disease but are estimated to have saved about US$900 million in malaria case management costs to public providers in sub-Saharan Africa between 2000 and 2014.Investments in malaria programmes can not only reduce malaria morbidity and mortality,thereby contributing to the health targets of the Sustainable Development Goals,but they can also transform the well-being and livelihood of some of the poorest communities across the globe. | Richard E.Cibulskis Pedro Alonso John Aponte Maru Aregawi Amy Barrette Laurent Bergeron Cristin A.Fergus Tessa Knox Michael Lynch Edith Patouillard Silvia Schwarte Saira Stewart Ryan Williams | 2016 | Infectious Diseases of Poverty2016，5，1： | 4 |
| 4 | FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer显示文摘Pancreatic cancer is an extremely aggressive disease; although progress has been made in the last few years, the prognosis of these patients remains dismal. FOLFIRINOX is now considered a standard treatment in first-line setting, since it demonstrated an improved overall and progression-free survival vs gemcitabine alone. However, the enthusiasm over the benefit of this three-drug regimen is tempered by the associated increased toxicity profile, and many efforts have been made to improve the feasibility of this schedule. After a more recent phase Ⅲ trial showing an improved outcome over gemcitabine, the combination of gemcitabine/nab-paclitaxel emerged as another standard first-line treatment. However, this treatment is also associated with more side effects. In addition, despite initial promising data on the predictive role of SPARClevels, recent studies showed that these levels are not associated with nab-paclitaxel efficacy. The choice to use this treatment over FOLFIRINOX is therefore a topic of debate, also because no validated biomarkers to guide FOLFIRINOX treatment are available. In the era of actionable mutations and target agents it would be desirable to identify molecular factors or biomarkers to predict response to therapy in order to maximize the efficacy of treatment and avoid useless toxic effects for non-responding patients. However, until today the milestone of treatment for pancreatic cancer remains chemotherapy combinations, without predictive or monitoring tools existing to optimize therapy. This review analyzes the state-of-the-art treatments, promises and limitations of targeted therapies, ongoing trials and future perspectives, including potential role of microR NAs as predictive biomarkers. | Chiara Caparello Laura L Meijer Ingrid Garajova Alfredo Falcone Tessa Y Le Large Niccola Funel Geert Kazemier Godefridus J Peters Enrico Vasile Elisa Giovannetti | 2016 | World Journal of Gastroenterology2016，22，31： | 4 |
| 5 | Observation of an α-synuclein liquid droplet state and its maturation into Lewy body-like assemblies显示文摘Misfoldedα-synudein is a major component of Lewy bodies,which are a hallmark of Parkinson's disease(PD).A large body of evidence shows thatα-synuclein can aggregate into amyloid fibrils,but the relationship between a-synuclein self-assembly and Lewy body formation remains unclear.Here,we show,both in vitro and in a Caenorhabditis elegans model of PD,thatα-synuclein undergoes liquid-liquid phase separation by forming a liquid droplet state,which converts into an amyloid-rich hydrogel with Lewy-body-like properties.This maturation process towards the amyloid state is delayed in the presence of model synaptic vesicles in vitro.Taken together,these results suggest that the formation of Lewy bodies may be linked to the arrested maturation ofα-synuclein condensates in the presence of lipids and other cellular components. | Maarten C.Hardenberg Tessa Sinnige Sam Casford Samuel T.Dada Chetan Poudel Elizabeth A.Robinson Monika Fuxreiter Clemens F.Kaminksi Gabriele S.Kaminski Schierle Ellen A.A.Nollen Christopher M.Dobson Michele Vendruscolo | 2021 | Journal of Molecular Cell Biology2021，13，4： | 3 |
| 6 | Delayed peripheral nerve repair: methods, including surgical ‘cross-bridging' to promote nerve regeneration显示文摘Despite the capacity of Schwann cells to support peripheral nerve regeneration, functional recovery after nerve injuries is frequently poor, especially for proximal injuries that require regenerating axons to grow over long distances to reinnervate distal targets. Nerve transfers, where small fascicles from an adjacent intact nerve are coapted to the nerve stump of a nearby denervated muscle, allow for functional return but at the expense of reduced numbers of innervating nerves. A 1-hour period of 20 Hz electrical nerve stimulation via electrodes proximal to an injury site accelerates axon outgrowth to hasten target reinnervation in rats and humans, even after delayed surgery. A novel strategy of enticing donor axons from an otherwise intact nerve to grow through small nerve grafts(cross-bridges) into a denervated nerve stump, promotes improved axon regeneration after delayed nerve repair. The efficacy of this technique has been demonstrated in a rat model and is now in clinical use in patients undergoing cross-face nerve grafting for facial paralysis. In conclusion, brief electrical stimulation, combined with the surgical technique of promoting the regeneration of some donor axons to ‘protect' chronically denervated Schwa nn cells, improves nerve regeneration and, in turn, functional outcomes in the management of peripheral nerve injuries. | Tessa Gordon Placheta Eva Gregory H.Borschel | 2015 | Neural Regeneration Research2015，10，10： | 3 |
| 7 | Effect of peroral endoscopic myotomy on esophagogastric junction physiology in patients with achalasia显示文摘 | Tessa Verlaan Wout O. Rohof Albert J. Bredenoord Susanne Eberl Thomas R?sch Paul Fockens | 2013 | Gastrointestinal Endoscopy2013，，1： | 2 |
| 8 | FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation显示文摘Tyrosine kinase inhibitors(TKIs)targeting FLT3 have shown activity but when used alone have achieved limited success in clinical trials,suggesting the need for combination with other drugs.We investigated the combination of FLT3 TKIs(Gilteritinib or Sorafenib),with Venetodax,a BCL-2 selective inhibitor(BCL-2i),on FLT3/ITD leukemia cells.The combination of a FLT3 TKI and a BCL-2i synergistically reduced cell proliferation and enhanced apoptosis/cell death in FLT3/ITD cell lines and primary AML samples.Venetoclax also re-sensitized FLT3 TKI-resistant cells to Gilteritinib or Sorafenib treatment,mediated through MAPK pathway inhibition.Gilteritinib treatment alone dissociated BIM from MCL-1 but increased the binding of BIM to BCL-2.Venetoclax treatment enhanced the binding of BIM to MCL-1 but dissociated BIM from BCL-2.Treatment with the drugs together resulted in dissociation of BIM from both BCL-2 and MCL-1,with an increased binding of BIM to the cell death mediator BAX,leading to increased apoptosis.These findings suggest that Venetoclax mitigates the unintended pro-survival effects of FLT3 TKI mainly through the dissociation of BIM and BCL-2 and also decreased BIM expression.This study provides evidence that the addition of BCL-2i enhances the effect of FLT3 TKI therapy in FLT3/ITD AML treatment. | Ruiqi Zhu Li Li Bao Nguyen Jaesung Seo Min Wu Tessa Seale Mark Levis Amy Duffield Yu Hu Donald Small | 2021 | Signal Transduction and Targeted Therapy2021，6，6： | 2 |
| 9 | Microchimerism in recurrent miscarriage显示文摘在怀孕期间,在 microchimerism 的获得的结果,它经久地装在两个接受者坚持的母亲胎儿的房间交换。自然地获得的 microchimerism 可以在怀孕影响母亲胎儿的相互作用。我们进行了研究问一个女人从她的自己的母亲获得了的 microchimerism 是否是可检测的在前或在在有周期性的流产的女人的怀孕期间。胎儿的 microchimerism 也是 assayed。有主要自发的周期性的流产的女人(n= 23 ) 并且控制(n= 31 ) 被学习。Genotyping 为 probands,他们的母亲和胎儿,被进行识别的非分享的多型性和量的聚合酶链反应表现了测量 microchimerismin 外设血 mononuclear 房间。预想比较在周期性的流产题目和控制之间被做,用逻辑回归和 Wilcoxon 等级和。在周期性的流产题目的随后的怀孕的纵的 microchimerism 被描述。向在周期性的流产对控制的 microchimerism 的更低的预想察觉有一个趋势, 6 %对 19 %(1/16 对 6/31, P= 0.2 ) 。在怀孕期间, 3/11 (27 %) 继续了有的周期性的流产题目,出生从他们的自己的母亲有 microchimerism 的察觉,而任何一个继续了流产的二个题目都没有察觉(0/2 ) 。这个起始的数据当可检测时,与周期性的流产在女人从一个女人的自己的母亲建议那 microchimerism,可以不同于控制并且根据随后的怀孕结果。进一步的研究被需要在周期性的流产决定房间类型,数量和 microchimerism 的任何潜在的功能的角色。 | Hilary S Gammill Mary D Stephenson Tessa M Aydelotte J Lee Nelson | 2014 | Cellular & Molecular Immunology2014，11，6： | 2 |
| 10 | HCV ‐associated B ‐cell non‐ H odgkin lymphomas and new direct antiviral agents显示文摘 | Paul Carrier Arnaud Jaccard Jérémie Jacques Tessa Tabouret Marilyne Debette‐Gratien Julie Abraham Laura Mesturoux Pierre Marquet Sophie Alain Denis Sautereau Marie Essig Véronique Loustaud‐Ratti | 2015 | Liver Int2015，，10： | 2 |
| 11 | Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib显示文摘 | Ling Li Lisheng Wang Liang Li Zhiqiang Wang Yinwei Ho Tinisha McDonald Tessa L. Holyoake WenYong Chen Ravi Bhatia | 2012 | Cancer Cell2012，，2： | 2 |
| 12 | Intraperitoneal cancer dissemination: Mechanisms of the patterns of spread显示文摘 | C. Pablo Carmignani Tessa A. Sugarbaker Christina M. Bromley Paul H. Sugarbaker | 2003 | Cancer and Metastasis Reviews2003，，： | 2 |
| 13 | Peroral Endoscopic Myotomy for the Treatment of Achalasia: An International Prospective Multicenter Study显示文摘 | Daniel Von Renteln Karl–Hermann Fuchs Paul Fockens Peter Bauerfeind Melina C. Vassiliou Yuki B. Werner Gerald Fried Wolfram Breithaupt Henriette Heinrich Albert J. Bredenoord Jan F. Kersten Tessa Verlaan Michael Trevisonno Thomas R?sch | 2013 | Gastroenterology2013，，2： | 2 |
| 14 | Brief post-surgical electrical stimulation accelerates axon regeneration and muscle reinnervation without affecting the functional measures in carpal tunnel syndrome patients显示文摘 | Tessa Gordon Nasim Amirjani David C. Edwards K. Ming Chan | 2009 | Experimental Neurology2009，，1： | 2 |
| 15 | C-MYB trans-activates the Human DNA Topoisomerase IIa Gene Promoter 显示文摘 | Tessa L Brandt David J | 1997 | J Biol Chem1997，272，10： | 1 |
| 16 | Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer?s disease显示文摘 | Paulina V. Arriagada John H. Growdon E. Tessa Hedley-Whyte Bradley T. Hyman | 1992 | Neurology1992，，3： | 1 |
| 17 | BTG1, a member of a new family of antiproliferative genes显示文摘 | Rouault JP Rimokh R Tessa C | 1992 | EMBO J1992，11，： | 1 |
| 18 | Axonal regeneration in the peripheral and central nervous systems-current Issues and advances显示文摘 | Keith F Tessa G | 2004 | Can J Neurol Sci2004，31，： | 1 |
| 19 | A whole-brain analysis in de novo Parkinson disease显示文摘 | Tessa C Giannelli M Della Nave R | | 0，，： | 1 |
| 20 | Multimodal management of stages III–IVa malignant thymoma显示文摘 | S Bretti A Berruti C Loddo P Sperone C Casadio M Tessa F Ardissone G Gorzegno M Sacco E Manzin P Borasio G.L Sannazzari G Maggi L Dogliotti | 2003 | Lung Cancer2003，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员